Cited by 690Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 46 of the 51 references it cites were found in a registry or an index.

The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

Open access

Scagliotti, Giorgio, Hanna, Nasser, Fossella, Frank, Sugarman, Katherine, Blatter, Johannes, Peterson, Patrick, Simms, Lorinda, Shepherd, Frances A.·2009·The Oncologist

DOI 10.1634/theoncologist.2008-0232

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Recent studies of pemetrexed have identified a predictive role for non-small cell lung cancer (NSCLC) histology. We further reviewed the differential efficacy of pemetrexed according to histology in two large, phase III NSCLC trials. METHODS: One study tested pemetrexed versus docetaxel in previously treated patients (n = 571) and the other tested cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemotherapy-naive patients (n = 1,725) with advanced NSCLC. Cox proportional hazard models were used to test for covariate-adjusted treatment-by-histology interactions (THIs) for overall survival (OS) and progression-free survival (PFS). For each histologic subgroup, the Kaplan-Meier method was used to estimate unadjusted within-arm medians, and Cox models were used to estimate covariate-adjusted between-arm hazard ratios (HRs). RESULTS: In both studies, treatment arms were well balanced for histology. THIs were statistically significant (p < .005) for both OS and PFS. Nonsquamous patients treated with pemetrexed-based therapy experienced longer survival than the comparators (HR, 0.78 and 0.84, respectively), whereas squamous patients had shorter survival (HR, 1.56 and 1.23, respectively). Whereas the efficacy of pemetrexed regimens differed according to histology, it did not differ for docetaxel or for cisplatin plus gemcitabine. Pemetrexed was well tolerated across histologic groups. CONCLUSIONS: The consistency of these results across studies confirms the predictive effect of histology for pemetrexed and the survival advantage for pemetrexed in patients with nonsquamous histology. These analyses suggest pemetrexed should not be recommended for the treatment of squamous cell carcinoma, but, because of efficacy and safety advantages, pemetrexed may be preferable to other agents for treatment of patients with nonsquamous NSCLC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2008-0232

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,524
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Self-citation
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Self-citation
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079

Flagged first, then by citations

Show all 51 references

5 of the 51 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Jiroutek, 1998, Prognostic factors in advanced non-small cell lung cancer (NSCLC): Analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981–1992, Proc Am Soc Clin Oncol, 17, 461a
National Cancer Institute, 1999, Common Toxicity Criteria v2.0 (CTC)

Sorted by citations

Items 101–200 of 687

Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer
Hida, T., Nishio, M., Nogami, N., Ohe, Y., Nokihara, H., Sakai, H., Satouchi, M., Nakagawa, K., Takenoyama, M., Isobe, H., et al. (2017) · Cancer Science · doi:10.1111/cas.13225 · Cited by 62
A novel voltammetric sensor based on palladium nanoparticles/carbon nanofibers/ionic liquid modified carbon paste electrode for sensitive determination of anti-cancer drug pemetrexed
Afzali, M., Mostafavi, A., Nekooie, R., & Jahromi, Z. (2019) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2019.03.041 · Cited by 62
The Importance of a Satisfactory Biopsy for the Diagnosis of Lung Cancer in the Era of Personalized Treatment
Ofiara, L., Navasakulpong, A., Ezer, N., & Gonzalez, A. V. (2012) · Current Oncology · doi:10.3747/co.19.1062 · Cited by 61
Uracil–DNA Glycosylase Expression Determines Human Lung Cancer Cell Sensitivity to Pemetrexed
Weeks, L. D., Fu, P., & Gerson, S. L. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0172 · Cited by 59
Squamous Cell Carcinoma Transformation from EGFR-mutated Lung Adenocarcinoma: A Case Report and Literature Review
Izumi, H., Yamasaki, A., Ueda, Y., Sumikawa, T., Maeta, H., Nakamoto, S., & Shimizu, E. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.10.005 · Cited by 61
A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma
Gbolahan, O. B., Porter, R. F., Salter, J. T., Yiannoutsos, C. T., Burns, M., Chiorean, E. G., & Loehrer, P. J. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.094 · Cited by 61
Divergent Genomic and Epigenomic Landscapes of Lung Cancer Subtypes Underscore the Selection of Different Oncogenic Pathways during Tumor Development
Lockwood, W. W., Wilson, I. M., Coe, B. P., Chari, R., Pikor, L. A., Thu, K. L., Solis, L. M., Nunez, M. I., Behrens, C., Yee, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037775 · Cited by 59
MiR-205 and MiR-375 MicroRNA Assays to Distinguish Squamous Cell Carcinoma from Adenocarcinoma in Lung Cancer Biopsies
Patnaik, S. K., Mallick, R., Kannisto, E. D., Sharma, R., Bshara, W., Yendamuri, S., & Dhillon, S. S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000423 · Cited by 58
Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States
Hess, L. M., Han, Y., Zhu, Y. E., Bhandari, N. R., & Sireci, A. N. (2021) · BMC Cancer · doi:10.1186/s12885-020-07714-3 · Cited by 58
Pemetrexed in the treatment of advanced non-squamous lung cancer
Rossi, A., Ricciardi, S., Maione, P., de Marinis, F., & Gridelli, C. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.06.006 · Cited by 58
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin–pemetrexed versus cisplatin–gemcitabine in advanced non-small-cell lung cancer
Syrigos, K. N., Vansteenkiste, J., Parikh, P., von Pawel, J., Manegold, C., Martins, R. G., Simms, L., Sugarman, K. P., Visseren‐Grul, C., & Scagliotti, G. V. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp392 · Cited by 58
Self-citation
Distinguishing Lung Adenocarcinoma from Lung Squamous Cell Carcinoma by Two Hypomethylated and Three Hypermethylated Genes: A Meta-Analysis
Huang, T., Li, J., Zhang, C., Hong, Q., Jiang, D., Ye, M., & Duan, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149088 · Cited by 58
Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study
Pirker, R., Pereira, J. R., Szczęsna, A., von Pawel, J., Krzakowski, M. J., Ramlau, R., Vynnychenko, I. O., Park, K., Eberhardt, W., de Marinis, F., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.03.010 · Cited by 57
Targeting Metabolic Changes in Cancer: Novel Therapeutic Approaches
Bobrovnikova-Marjon, E. V., & Hurov, J. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112344 · Cited by 56
Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
Huang, M., Lou, Y., Pellissier, J. M., Burke, T. A., Liu, F. X., Xu, R., & Velcheti, V. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1230123 · Cited by 58
Inhibition of MEK/ERK activation attenuates autophagy and potentiates pemetrexed-induced activity against HepG2 hepatocellular carcinoma cells
Tong, Y., Huang, H., & Pan, H. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.11.038 · Cited by 55
Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Cohen, M. H., Cortazar, P., Justice, R. L., & Pazdur, R. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0224 · Cited by 55
The Importance of Multidisciplinary Team Management of Patients with Non-Small-Cell Lung Cancer
Ellis, P. M. (2012) · Current Oncology · doi:10.3747/co.19.1069 · Cited by 54
Tissue-Sparing Application of the Newly Proposed IASLC/ATS/ERS Classification of Adenocarcinoma of the Lung Shows Practical Diagnostic and Prognostic Impact
Sterlacci, W., Savic, S., Schmid, T. A., Oberaigner, W., Auberger, J., Fiegl, M., & Tzankov, A. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcp77kmkjxnmpms · Cited by 53
Personalized Medicine for Non–Small-Cell Lung Cancer: Implications of Recent Advances in Tissue Acquisition for Molecular and Histologic Testing
Moreira, A. L., & Thornton, R. H. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.01.004 · Cited by 52
Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung
Takamochi, K., Ohmiya, H., Itoh, M., Mogushi, K., Saito, T., Hara, K., Mitani, K., Kogo, Y., Yamanaka, Y., Kawai, J., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2792-1 · Cited by 52
Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer
Schiller, J. H., von Pawel, J., Schütt, P., Ansari, R., Thomas, M., Saleh, M. N., McCroskey, R. D., Pfeifer, W., Marsland, T., Kloecker, G. H., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f4a5c9 · Cited by 51
Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome
Ding, R., Prasanna, P., Corredor, G., Barrera, C., Zens, P., Lu, C. Y., Velu, P., Leo, P., Beig, N. G., Li, H., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00277-5 · Cited by 50
A single EBUS-TBNA procedure can support a large panel of immunohistochemical stains, specific diagnostic subtyping, and multiple gene analyses in the majority of non–small cell lung cancer cases
Rooper, L. M., Nikolskaia, O. V., Carter, J. H., Ning, Y., Lin, M., & Maleki, Z. (2016) · Human Pathology · doi:10.1016/j.humpath.2015.12.025 · Cited by 50
Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer
Rudin, C. M., Mauer, A. M., Šmakal, M., Juergens, R. A., Špelda, S., Wertheim, M. S., Coates, A., McKeegan, E. M., Ansell, P. J., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5944 · Cited by 49
Chemotherapy for lung cancer: the state of the art in 2009
Higgins, M. J., & Ettinger, D. S. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.115 · Cited by 49
Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer: Results of an Exploratory Subgroup Analysis of a Phase III Trial
Yang, C.-H., Simms, L., Park, K., Lee, J. S., Scagliotti, G. V., & Orlando, M. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d1273d · Cited by 48
Self-citation
Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials
Treat, J., Scagliotti, G. V., Peng, G., Monberg, M., Obasaju, C. K., & Socinski, M. A. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.10.021 · Cited by 48
Self-citation
Two MicroRNA Panels to Discriminate Three Subtypes of Lung Carcinoma in Bronchial Brushing Specimens
Huang, W., Hu, J., Yang, D., Fan, X.-T., Jin, Y., Hou, Y., Wang, J., Yuan, Y., Tan, Y.-S., Zhu, X., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0534oc · Cited by 48
Role of Pemetrexed in Sdvanced Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Controlled Trials, with Histology Subgroup Analysis
AlSaleh, K. A., Quinton, C. L., & Ellis, P. M. (2012) · Current Oncology · doi:10.3747/co.19.891 · Cited by 50
Afatinib in the treatment of EGFR mutation-positive NSCLC – A network meta-analysis
Popat, S., Mok, T. S. K., Yang, J. C., Wu, Y.-L. L. C., Lungershausen, J., Stammberger, U. M., Griebsch, I., Fonseca, T., & Paz-Ares, L. G. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.05.007 · Cited by 48
Advances in Fine Needle Aspiration Cytology for the Diagnosis of Pulmonary Carcinoma
Hasanovic, A., Rekhtman, N., Sigel, C., & Moreira, A. L. (2011) · Pathology Research International · doi:10.4061/2011/897292 · Cited by 48
Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
Farsi, A. M. A., & Ellis, P. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00157 · Cited by 47
Personalised medicine for nonsmall cell lung cancer
Mascaux, C., Tomasini, P., Greillier, L., & Barlési, F. (2017) · European Respiratory Review · doi:10.1183/16000617.0066-2017 · Cited by 49
Histology and Smoking Status Predict Survival of Patients with Advanced Non–Small-Cell Lung Cancer: Results of West Japan Oncology Group (WJOG) Study 3906L
Kogure, Y., Ando, M., Saka, H., Chiba, Y., Yamamoto, N., Asami, K., Hirashima, T., Seto, T., Nagase, S., Otsuka, K., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828b51f5 · Cited by 45
Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor in Non–Small-Cell Lung Cancer Harboring EGFR Mutation
Tanaka, K., Hata, A., Kaji, R., Fujita, S., Otoshi, T., Fujimoto, D., Kawamura, T., Tamai, K., Takeshita, J., Matsumoto, T., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828c3929 · Cited by 46
Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas
Noh, S., & Shim, H. S. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.09.008 · Cited by 46
Pemetrexed in advanced non-small-cell lung cancer
Fuld, A. D., Dragnev, K. H., & Rigas, J. R. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.482560 · Cited by 46
The Cost of Treating Advanced Non-Small Cell Lung Cancer: Estimates from the Chinese Experience
Zeng, X., Karnon, J. D., Wang, S., Wu, B. Y., Wan, X., & Peng, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048323 · Cited by 46
Cytologic subtyping of lung adenocarcinoma by using the proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) adenocarcinoma classification
Rodriguez, E. F., Monaco, S. E., & Đačić, S. (2013) · Cancer Cytopathology · doi:10.1002/cncy.21314 · Cited by 45
Diverging prognostic impacts of hypoxic markers according to NSCLC histology
Andersen, S., Eilertsen, M., Dønnem, T., Al-Shibli, K. I., Al‐Saad, S., Busund, L., & Bremnes, R. M. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.10.006 · Cited by 45
Classification of Non-Small Cell Lung Cancer Based on Copy Number Alterations
Li, B., You, J., Huang, T., & Cai, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088300 · Cited by 44
Crizotinib in the Treatment of Non–Small-Cell Lung Cancer
Rothschild, S. I., & Gautschi, O. P. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.04.006 · Cited by 46
Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come
Toschi, L., Rossi, S., Finocchiaro, G., & Santoro, A. (2017) · ecancermedicalscience · doi:10.3332/ecancer.2017.787 · Cited by 48
The Role of Histology with Common First-line Regimens for Advanced Non-small Cell Lung Cancer: A Brief Report of the Retrospective Analysis of a Three-arm Randomized Trial
Scagliotti, G. V., de Marinis, F., Rinaldi, M., Crinò, L., Gridelli, C., Ricci, S., Zhao, Y. D., Liepa, A. M., Peterson, P. M., & Tonato, M. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c06980 · Cited by 44
Self-citation
Associations between TS, TTF-1, FR-α, FPGS, and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin or Gemcitabine Plus Carboplatin as First-Line Chemotherapy
Grønberg, B. H., Lund‐Iversen, M., Strøm, E. H., Brustugun, O. T., & Scott, H. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182a406a3 · Cited by 44
Optimizing Tissue Sampling for the Diagnosis, Subtyping, and Molecular Analysis of Lung Cancer
Ofiara, L., Navasakulpong, A., Beaudoin, S., & Gonzalez, A. V. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00253 · Cited by 44
Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements
Park, S., Park, T. S., Choi, C., Lee, K. H., Kim, S., Lee, J., Kim, W. S., Song, J. S., & Lee, J. C. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.01.003 · Cited by 45
Curcumin inhibits human non-small cell lung cancer xenografts by targeting STAT3 pathway.
Xu, X., & Zhu, Y. (2017) · PubMed Central · Cited by 44
Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study
Kakimi, K., Matsushita, H., Masuzawa, K., Karasaki, T., Kobayashi, Y., Nagaoka, K., Hosoi, A., Ikemura, S., Kitano, K., Kawada, I., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001185 · Cited by 48
Treatment of advanced non-small-cell lung cancer
Prabhash, K., Vora, A. D., Limaye, S. A., Sahoo, T. P., Batra, U., Patil, S., Patil, V., Noronha, V., Bhosale, B., Raut, N. V., et al. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_61_21 · Cited by 46
A Systematic Review of the Interobserver Variability for Histology in the Differentiation between Squamous and Nonsquamous Non-small Cell Lung Cancer
Paech, D., Weston, A. R., Pavlakis, N., Gill, A. J., Rajan, N., Barraclough, H., Fitzgerald, B., & Kooten, M. V. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181fc0878 · Cited by 43
Overexpression of T ‐ LAK cell‐originated protein kinase predicts poor prognosis in patients with stage I lung adenocarcinoma
Wei, D., Yeh, Y., Hung, J., Chou, T., Wu, Y., Lu, P., Cheng, H., Hsu, Y., Kuo, Y., Chen, K., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02197.x · Cited by 43
Current management of RET rearranged non-small cell lung cancer
Stinchcombe, T. E. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920928634 · Cited by 43
Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations
Wu, S., Yang, C.-H., Yu, C., Lee, J., Hsu, Y.-C., Chang, Y., Shih, J., & Yang, P. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.10.012 · Cited by 42
Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer
Siddiqui, A., Gollavilli, P. N., Ramesh, V., Parma, B., Schwab, A., Vazakidou, M. E., Natesan, R., Saatci, Ö., Rapa, I., Bironzo, P., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01095-x · Cited by 41
Expression Profiling-Based Subtyping Identifies Novel Non-small Cell Lung Cancer Subgroups and Implicates Putative Resistance to Pemetrexed Therapy
Hou, J., Lambers, M. E. H., den Hamer, B., den Bakker, M. A., Hoogsteden, H. C., Grosveld, F. G., Hegmans, J. P., Aerts, J. G. J. V., & Philipsen, S. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182352a45 · Cited by 41
Development and Validation of a Prognostic Gene-Expression Signature for Lung Adenocarcinoma
Park, Y.-Y., Park, E. S., Kim, S. B., Kim, S. C., Sohn, B. H., Chu, I., Jeong, W., Mills, G. B., Byers, L. A., & Lee, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044225 · Cited by 41
Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer.
Langer, C. J. (2011) · PubMed · Cited by 40
Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study
Scagliotti, G. V., Park, K., Patil, S. G., Rolski, J., Göksel, T., Martins, R. G., Gans, S. J. M., Visseren‐Grul, C., & Peterson, P. M. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.04.033 · Cited by 41
Self-citation
Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
Chiappori, A., Bepler, G., Barlési, F., Soria, J., Reck, M., Bearz, A., Barata, F. J., Scagliotti, G. V., Park, K., Wagle, A., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181cee24f · Cited by 40
Self-citation
Extending Survival of Stage IV Non-Small Cell Lung Cancer
Carnio, S., Novello, S., Mele, T., Levra, M. G., & Scagliotti, G. V. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.013 · Cited by 40
Self-citation
Cytotoxicity study and influence of SBA-15 surface polarity and pH on adsorption and release properties of anticancer agent pemetrexed
Almáši, M., Beňová, E., Zeleňák, V., Madaj, B., Huntošová, V., Brus, J., Urbanová, M., Bednarčík, J., & Hornebecq, V. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.110552 · Cited by 42
Novel Approaches of Chemoradiotherapy in Unresectable Stage IIIA and Stage IIIB Non-Small Cell Lung Cancer
Stinchcombe, T. E., & Bogart, J. A. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0020 · Cited by 39
Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial
Ridolfi, L. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1099 · Cited by 40
Stilbene Compounds Inhibit Tumor Growth by the Induction of Cellular Senescence and the Inhibition of Telomerase Activity
Lee, Y., Chen, Y.-Y., Yeh, Y.-L., Wang, Y., & Chen, R.-J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112716 · Cited by 39
Pemetrexed
Baldwin, C. M., & Perry, C. M. (2009) · Drugs · doi:10.2165/11202640-000000000-00000 · Cited by 39
Histologic Classification of Non-Small-Cell Lung Cancer over Time: Reducing the Rates of Not-Otherwise-Specified
Ho, C., Tong, K. M., Ramsden, K., Ionescu, D. N., & Laskin, J. J. (2015) · Current Oncology · doi:10.3747/co.22.2339 · Cited by 38
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
Tanaka, F., Wada, H., Fukui, Y., & Fukushima, M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq730 · Cited by 38
Radio(chemo)therapy in locally advanced nonsmall cell lung cancer
Glatzer, M., Eliçin, O., Ramella, S., Nestle, U., & Putora, P. M. (2016) · European Respiratory Review · doi:10.1183/16000617.0053-2015 · Cited by 38
Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer
Shen, C., Kehl, K. L., Zhao, B., Simon, G. R., Zhou, S., & Giordano, S. H. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.11.002 · Cited by 38
Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States
Ramalingam, S., Dinan, M. A., & Crawford, J. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.007 · Cited by 38
Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer
Metzenmacher, M., Váraljai, R., Hegedűs, B., Cima, I., Förster, J., Schramm, A. R., Scheffler, B., Horn, P., Klein, C. A., Szarvas, T., et al. (2020) · Cancers · doi:10.3390/cancers12020353 · Cited by 38
Subtyping Non–Small Cell Lung Cancer
Rossi, G., Pelosi, G., Barbareschi, M., Graziano, P., Cavazza, A., & Papotti, M. G. (2013) · International Journal of Surgical Pathology · doi:10.1177/1066896913489346 · Cited by 38
Aberrant methylation of N-methyl-D-aspartate receptor type 2B (NMDAR2B) in non-small cell carcinoma
Tamura, H., Suzuki, M., Moriya, Y., Hoshino, H., Okamoto, T., Yoshida, S., & Yoshino, I. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-220 · Cited by 38
Update on systemic therapy of advanced non-small-cell lung cancer
Čufer, T., & Knez, L. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.940327 · Cited by 37
Melittin suppresses growth and induces apoptosis of non-small-cell lung cancer cells via down-regulation of TGF-β-mediated ERK signal pathway
Yu, R., Wang, M., Wang, M., & Han, L. (2020) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20209017 · Cited by 37
Thymidylate synthase inhibitors for non-small cell lung cancer
Galvani, E., Peters, G. J., & Giovannetti, E. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.617742 · Cited by 36
Lung Cancer Genotype-Based Therapy and Predictive Biomarkers: Present and Future
Cagle, P. T., & Allen, T. C. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0508-ra · Cited by 36
A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non–Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements
Riess, J. W., Padda, S. K., Bangs, C. D., Das, M. S., Neal, J. W., Adrouny, A., Cherry, A. M., & Wakelee, H. A. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.04.008 · Cited by 36
Optimizing the Management of Advanced Non-small-Cell Lung Cancer: A Personal View
Vincent, M. D. (2009) · Current Oncology · doi:10.3747/co.v16i4.465 · Cited by 36
Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer
Lazzari, C., Bulotta, A., Ducceschi, M., Viganò, M. G., Brioschi, E., Corti, F., Gianni, L., & Gregorc, V. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00004 · Cited by 37
Potential Predictors of Sensitivity to Pemetrexed as First-line Chemotherapy for Patients with Advanced Non-Squamous NSCLCs
Lu, Y.-Y., Huang, X., Xu, L., Liu, D.-G., Cao, J., Wu, X., Liu, J., & Xiang, J. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.3.2005 · Cited by 35
Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer
Socinski, M. A., Raju, R. N., Stinchcombe, T. E., Kocs, D. M., Couch, L. S., Barrera, D., Rousey, S. R., Choksi, J. K., Jotte, R. M., Patt, D. A., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181fd42eb · Cited by 35
Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer
Jakobsen, J. N., Santoni‐Rugiu, E., Ravn, J. B., & Sørensen, J. B. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.003 · Cited by 35
Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer
Paz-Ares, L. G., Altuǧ, S., Vaury, A. T., Jaime, J. C., Russo, F. P., & Visseren‐Grul, C. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-85 · Cited by 35
Molecular Predictors of Response to Chemotherapy in Non-Small Cell Lung Cancer
Andrews, J., Yeh, P. G., Pao, W. J., & Horn, L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318213f3cf · Cited by 35
Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non–Small-Cell Lung Cancer
Hirsch, F. R., Govindan, R., Zvirbule, Z., Braiteh, F., Rittmeyer, A., Belda-Iniesta, C., Isla, D., Cosgriff, T. M., Boyer, M., Ueda, M., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.05.011 · Cited by 35
Platinum rechallenge in patients with advanced NSCLC: A pooled analysis
Petrelli, F., Coinu, A., Cabiddu, M., Ghilardi, M., Ardine, M., & Barni, S. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.06.022 · Cited by 35
Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer
Wu, Y.-L. L. C., Lü, S., Cheng, Y., Zhou, C., Wang, M., Qin, S., Lü, Y., Zhang, Y., Zhu, Y., Song, X., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.07.007 · Cited by 35
Phase I Trial of Radiation With Concurrent and Consolidation Pemetrexed and Cisplatin in Patients With Unresectable Stage IIIA/B Non–Small-Cell Lung Cancer
Brade, A. M., Bezjak, A., MacRae, R. M., Laurie, S. A., Sun, A. Y., Cho, J., Leighl, N. B., Pearson, S., Southwood, B., Wang, L. E., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.01.014 · Cited by 35
Self-citation
Pemetrexed in patients with thymic malignancies previously treated with chemotherapy
Liang, Y., Padda, S. K., Riess, J. W., West, R. B., Neal, J. W., & Wakelee, H. A. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.11.006 · Cited by 34
Nintedanib Plus Docetaxel as Second-Line Therapy in Patients with Non-Small-Cell Lung Cancer: A Network Meta-Analysis
Popat, S., Mellemgaard, A., Fahrbach, K. R., Martin, A. L., Rizzo, M., Kaiser, R., Griebsch, I., & Reck, M. (2014) · Future Oncology · doi:10.2217/fon.14.290 · Cited by 34
Maintenance Therapy for Advanced Non-small Cell Lung Cancer: Current Status, Controversies, and Emerging Consensus
Owonikoko, T. K., Ramalingam, S. S., & Belani, C. P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2328 · Cited by 34
New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib
Hirsh, V. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s104177 · Cited by 36
Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis
Vickers, A. D., Winfree, K. B., Carter, G. C., Kiiskinen, U., Jen, M., Stull, D. E., Kaye, J. A., & Carbone, D. P. (2019) · BMC Cancer · doi:10.1186/s12885-019-5569-5 · Cited by 34
Histology as a treatment effect modifier in advanced non‐small cell lung cancer: A systematic review of the evidence
Standfield, L., Weston, A. R., Barraclough, H., Kooten, M. V., & Pavlakis, N. (2011) · Respirology · doi:10.1111/j.1440-1843.2011.02025.x · Cited by 34
Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Socinski, M. A. (2014) · Current Oncology · doi:10.3747/co.21.1997 · Cited by 34
Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer
Choi, C., Jang, S. J., Park, S.-Y., Choi∥, Y., Jeong, J.-H., Kim, D.-S., Kim, H. K., Park, K.-S., Nam, B., Kim, H.-R., et al. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-119 · Cited by 34
Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
Sun, J., Ahn, J. S., Park, K., Han, J., & Ahn, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.7579 · Cited by 34

Authors: Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., Simms, L., & Shepherd, F. A.
Affiliations: University of Turin (IT)
Indiana University Indianapolis (US)
The University of Texas MD Anderson Cancer Center (US)
Eli Lilly (United States) (US)
Eli Lilly (Germany) (DE)
Eli Lilly (Canada) (CA)
University of Toronto (CA)
Corresponding author: Scagliotti, Giorgio
ORCID: Scagliotti, Giorgio
Hanna, Nasser
Peterson, Patrick
Shepherd, Frances A.
Venue: The Oncologist
Publisher: Oxford University Press (OUP)
Published: 2009-02-16
Volume: 14
Issue: 3
Pages: 253-263
ISSN: 1083-7159 (ISSN-L)
1549-490X
DOI: 10.1634/theoncologist.2008-0232
OpenAlex: W2139939379
Cited by: 690
References: 51
Citations by year: 2026: 5 · 2025: 8 · 2024: 10 · 2023: 15 · 2022: 21 · 2021: 15 · 2020: 27 · 2019: 29 · 2018: 30 · 2017: 42 · 2016: 46 · 2015: 41 · 2014: 69 · 2013: 72 · 2012: 71
FWCI: 72.97
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations: The Oncologist (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Funders: Eli Lilly and Company
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: pemetrexed, non-small cell lung cancer, tumor histology, squamous cell carcinoma, docetaxel, overall survival, progression-free survival, predictive biomarkers
MeSH terms: Pemetrexed, Docetaxel, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Deoxycytidine, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Randomized Controlled Trials as Topic, Taxoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks